Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Myeloma/Amyloidosis: Therapy excluding Transplantation: Myeloma/Amyloidosis: Therapy excluding Transplantation

653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Relapsed/Refractory Multiple Myeloma

Watch Session

412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) clinically relevant abstract

Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.

 

413 A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma clinically relevant abstract

Michael Sebag, Nizar Bahlis, Christopher P. Venner, et al.

 

414 Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, Joseph Mikhael, Roman Hajek, et al.

 

415 Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex) clinically relevant abstract

Maria-Victoria Mateos, Enrique M. Ocio,  Anna Sureda Balari, et al.

 

416 Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (CPT-MM301)

Wenming Chen, Zhongjun Xia, Baijun Fang, et al.

 

417 ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, et al.